uPM3, a new molecular urine test for the detection of prostate cancer☆
To access this article, please choose from the options below
☆ Y. Fradet is also the Chief Scientific Officer for DiagnoCure Inc., which funded this trial. C. Chypre is the Director of Research & Development for DiagnoCure Inc.
PII: S0090-4295(04)00500-X
doi:10.1016/j.urology.2004.03.052
© 2004 Elsevier Inc. All rights reserved.
